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Abstract
Xeroderma pigmentosum (XP) is caused by defects in the nucleotide excision repair (NER) pathway. NER removes helix-
distorting DNA lesions, such as UV–induced photodimers, from the genome. Patients suffering from XP exhibit exquisite sun
sensitivity, high incidence of skin cancer, and in some cases neurodegeneration. The severity of XP varies tremendously
depending upon which NER gene is mutated and how severely the mutation affects DNA repair capacity. XPF-ERCC1 is
a structure-specific endonuclease essential for incising the damaged strand of DNA in NER. Missense mutations in XPF
can result not only in XP, but also XPF-ERCC1 (XFE) progeroid syndrome, a disease of accelerated aging. In an attempt
to determine how mutations in XPF can lead to such diverse symptoms, the effects of a progeria-causing mutation
(XPF
R153P) were compared to an XP–causing mutation (XPF
R799W) in vitro and in vivo. Recombinant XPF harboring either
mutation was purified in a complex with ERCC1 and tested for its ability to incise a stem-loop structure in vitro. Both mutant
complexes nicked the substrate indicating that neither mutation obviates catalytic activity of the nuclease. Surprisingly,
differential immunostaining and fractionation of cells from an XFE progeroid patient revealed that XPF-ERCC1 is abundant
in the cytoplasm. This was confirmed by fluorescent detection of XPF
R153P-YFP expressed in Xpf mutant cells. In addition,
microinjection of XPF
R153P-ERCC1 into the nucleus of XPF–deficient human cells restored nucleotide excision repair of UV–
induced DNA damage. Intriguingly, in all XPF mutant cell lines examined, XPF-ERCC1 was detected in the cytoplasm of a
fraction of cells. This demonstrates that at least part of the DNA repair defect and symptoms associated with mutations in
XPF are due to mislocalization of XPF-ERCC1 into the cytoplasm of cells, likely due to protein misfolding. Analysis of these
patient cells therefore reveals a novel mechanism to potentially regulate a cell’s capacity for DNA repair: by manipulating
nuclear localization of XPF-ERCC1.
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Introduction
Xeroderma pigmentosum (XP) is a rare autosomal recessive
disease characterized by photosensitivity and a greater than a
1000-fold increased risk of skin cancer in sun-exposed areas of
the skin [1]. In approximately 20% of patients, there is also
progressive neurodegeneration leading to loss of coordinated
motion, vision and hearing [2,3]. XP is caused by mutations in
genes that encode proteins required for nucleotide excision
repair (NER) of DNA. Eight complementation groups of XP
have been identified based on fusion studies with XP patient
cells. These complementation groups include XP-A through
XP-G and a variant, XP-V. The severity of XP varies
tremendously, with diagnosis occurring anywhere from infancy
to adulthood [1]. The severity of the disease is determined
largely by which gene is mutated and to what extent the
mutation affects NER.
NER removes helix-distorting lesions in DNA, for example
cyclobutane pyrimidine dimers (CPDs) and pyrimidine pyrimi-
done photoproducts (6–4PPs) caused by the ultraviolet (UV)
component of sunlight [4]. There are two ways by which DNA
damage is recognized in NER. Lesions anywhere in the genome
can be recognized by the complex XPC-RAD23B [5,6]. For some
lesions, this is facilitated by a second complex XPE/DDB2-DDB1
[7]. Alternatively, lesions that occur in the coding strand of DNA,
within transcribed regions, can trigger NER if they stall
progression of RNA polymerase II [8,9]. This requires CSA,
CSB and XAB2 [10–12]. Once the damage is recognized, the
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The basal transcription factor TFIIH is recruited to the site of
helix-distortion to unwind the DNA around the lesion, using two
of its ten subunits, XPB and XPD [8,13]. RPA and XPA bind the
unwound repair intermediate to stabilize it and recruit subsequent
factors. The damaged strand of DNA is then incised by two
structure-specific endonucleases, the heterodimer of XPF-ERCC1
and XPG, which cut 59 and 39 of the lesion, respectively [14–17].
This leads to removal of the lesion as part of a 24–32 base
oligonucleotide. The resultant gap is filled by the replication
machinery including RPA, PCNA, RF-C, DNA polymerase d/e,
and the backbone is sealed by DNA LIGI or LIGIIIa-XRCC3
[18–20].
XPF-ERCC1 is a highly conserved endonuclease that nicks
double-stranded DNA 59 to a junction with single-stranded DNA
[21]. In addition to NER, XPF-ERCC1 is involved in the repair
of DNA interstrand crosslinks (ICL) [22] and double-strand
breaks [23]. XPF and ERCC1 are paralogs thought to have
arisen by gene duplication of the conserved nuclease and helix-
hairpin helix protein-interaction domains [24]. The proteins
interact via their C-terminal helix-hairpin-helix domains and this
interaction is required to stabilize both proteins in vivo [25,26].
XPF contains the nuclease catalytic domain [27], whereas
ERCC1 mediates the interaction with XPA and recruitment to
NER complexes [28,29]. Unlike NER-specific proteins XPA and
XPC, XPF-ERCC1 appears to be essential for human develop-
ment or viability since no patients have yet been identified who
are homozygous for early nonsense or frameshift mutations in
either gene.
XP-A and XP-C are among the most common complementa-
tion groups in XP [30]. XP-C patients have severe skin
abnormalities but generally lack neurological symptoms [31]. In
contrast, XP-A patients show profound neurodegeneration, in
addition to cutaneous features [1]. XP-F patients typically have
very mild cutaneous features of XP, including late onset of skin
cancer, but often have complications due to neurodegeneration as
adults. It was recently discovered that mutations in XPF can lead
to a second disease, XFE progeroid syndrome (short for XPF-
ERCC1), characterized by spontaneous, accelerated aging of
multiple tissues, including the nervous system [32]. Herein, we
attempted to understand the molecular basis for how mutations in
XPF could lead to such diverse outcomes. This led to the surprising
discovery that mutation of XPF promotes mislocalization of XPF-
ERCC1 to the cytoplasm of cells.
Results
Characterization of R
153P-XPF-ERCC1 activity in vitro
We first asked if mutations in XPF that cause mild or severe
disease differentially affect the biochemical properties of XPF-
ERCC1. To answer this, we compared the biochemical properties
of XPF-ERCC1 from two patients, XP42RO (a patient with mild
XP, homozygous for a mutation causing an R
799W substitution in
XPF [33]) and XP51RO (a patient with XFE progeroid syndrome,
homozygous for a mutation causing an R
153P substitution in XPF
[32]) to that of wild type XPF-ERCC1. Recombinant XPF
WT-
ERCC1, XPF
R153P-ERCC1 and XPF
R799W-ERCC1 were puri-
fied from baculovirus-infected Sf9 insect cells using a His6 tag on
ERCC1. We previously reported [27] that our purified prepara-
tions of XPF
WT-ERCC1 elute from a gel-filtration column in three
fractions: (1) a minor fraction in the void volume (,45 ml)
containing aggregated, inactive protein; (2) active heterodimeric
XPF-ERCC1 at ,65 ml, which corresponds to a molecular
weight of ,200 kD, as expected, and (3) monomeric ERCC1,
which peaks at ,78 mL, which corresponds to ,50 kD.
Recombinant XPF
WT-ERCC1 eluted as expected (Figure 1A).
Both mutant protein complexes eluted with similar profiles that
differed substantially from that of XPF
WT-ERCC1. The majority
of the mutant complexes eluted at ,45 mL rather than at 65 ml,
indicating that they were aggregated. The peak at 78 ml,
corresponding to free ERCC1 was identical for both mutant and
WT XPF-ERCC1 preps. These results suggest that the mutations
in XPF that cause both mild and severe disease lead to protein
misfolding that does not interfere with ERCC1 binding, but does
lead to protein aggregation.
We were able to purify a small amount of XPF
R153P-ERCC1
and XPF
R799W-ERCC1 from the fractions eluting at 65 ml,
indicating that at least some of the mutant proteins are likely to be
properly folded. SDS-PAGE analysis of the complexes after an
additional purification step over a heparin column revealed
dramatically reduced yields of the complexes of XPF
R153P-ERCC1
and XPF
R799W-ERCC1 compared to XPF
WT-ERCC1 (Figure 1B).
Similarly, the amount of XPF protein detectable by immunoblot
in whole cell extracts of human fibroblasts harboring the XPF
R153P
and XPF
R799W mutations (XP51RO and XP42RO, respectively)
was reduced compared to normal cells (C5RO) (Figure 1C).
The catalytic activity of the purified heterodimers was
investigated by measuring their ability to incise a
32P-end-labeled
stem–loop DNA substrate at the single-strand:double-strand DNA
junction in the presence of 0.4 mM MnCl2 or 2 mM MgCl2 at a
2-fold molar excess of protein over substrate (Figure 1D). With
XPF
WT-ERCC1, .80% of the stem-loop substrate was cleaved.
Both XPF
R153P-ERCC1 and XPF
R799W-ERCC1 also incised the
DNA substrate, demonstrating that both mutant complexes retain
catalytic activity (Figure 1D, lanes 5 & 7). Incision by both mutant
complexes was reduced compared to the WT complex. This may
simply reflect the fact that preparations of mutant heteroduplexes
were less concentrated than XPF
WT-ERCC1 (Figure 1B), inevi-
tably leading to differences in the buffering conditions between
incision reactions.
We previously observed that mutant XPF-ERCC1 complexes
tend to be more active in the presence of Mn
2+ than Mg
2+ since
this metal has less stringent requirements for the proper alignment
of the active site residues [27]. Consistent with this, incision by
XPF
R153P-ERCC1 and XPF
R799W-ERCC1 was increased ,2-fold
in the presence of Mn
2+ compared to Mg
2+, whereas the cation
had no effect on incision by XPF
WT-ERCC1 (Figure 1D). These
data support the conclusion that even monomeric XPF
R153P and
XPF
R799W are to some extent misfolded. Notably, there was not a
Author Summary
XPF-ERCC1 is a nuclease that plays a critical role in DNA
repair. Mutations in XPF are linked to xeroderma pigmen-
tosum, characterized by sun sensitivity, high incidence of
skin cancer, and neurodegeneration, or XFE progeroid
syndrome, a disease of accelerated aging. Herein we report
the unexpected finding that mutations in XPF cause
mislocalization of XPF-ERCC1 to the cytoplasm. Recombi-
nant mutant XPF-ERCC1 derived from XP– and XFE–
causing alleles are catalytically active and if delivered to
the nucleus of cells restore DNA repair. This demonstrates
that protein mislocalization contributes to defective DNA
repair and disease arising as a consequence of mutations
in XPF. It also illustrates a novel mechanism of regulating a
cell’s capacity for DNA repair: by manipulating nuclear
localization of XPF-ERCC1 to enhance or inhibit repair and
to prevent cancer or tumor resistance to chemotherapy,
respectively.
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R153P-ERCC1
and XPF
R799W-ERCC1 on stem-loop DNA substrates, indicating
that the biochemical basis for the more severe phenotype
associated with the R
153P mutation is unlikely to be simply a loss
of catalytic activity.
Immunolocalization of XPF protein
R
153P is situated in a lysine-rich domain of XPF that might be
part of a complex nuclear localization sequence (NLS). Thus we
next asked if XPF
R153P-ERCC1 is mislocalized in cells. Differen-
tial immunofluorescence was used to identify the subcellular
localization of XPF-ERCC1 in XPF mutant cell lines that were co-
cultured with normal cells as an internal control [34]. XPF was
detected exclusively in the nucleus of normal fibroblasts (Figure 2A,
upper panel). In the same sample, XPF was detected in the
cytoplasm of XP51RO cells (harboring XPF
R153P). In XP42RO
cells (harboring XPF
R799W), the XPF signal was pancellular so that
the nucleus and cytoplasm could not be distinguished from one
another. To explore this further, we used immunofluorescence to
detect XPF in additional XP-F patient cell lines and to our surprise
discovered that in all mutant cell lines XPF was frequently
detected in the cytoplasm. In all cases, XPF mutant cell lines could
be discriminated from normal fibroblasts by the staining pattern of
the cell population: reduced nuclear XPF-ERCC1 and the
presence of cells in which the heterodimer was exclusively
cytoplasmic. This was true irrespective of the antibody used for
analysis [monoclonal 3F2 (Cancer Research UK), monoclonal
Ab-1 (Neomarkers), or polyclonal anti-XPF (Erasmus Medical
Centre)] (data not shown). This indicates that mislocalization of
XPF in the cytoplasm is a common consequence of XPF mutation.
This raised the possibility that misfolding of mutant XPF caused
abnormal subcellular localization of the protein. Therefore, next
we asked if these mutant XPF proteins still interacted with their
obligate binding partner ERCC1. ERCC1 was detected in the
nucleus of normal (wt) fibroblasts, as expected. However, like XPF,
ERCC1 was frequently detected in the cytoplasm of XPF mutant
cells (Figure 2B). All eight XPF mutant cells lines tested were
readily distinguished from wt cells by their ERCC1 staining
pattern. Furthermore, there was a strong correlation between the
staining pattern for ERCC1 and XPF in all cell lines. This
observation indicates that ERCC1 can interact with each of these
mutant XPF proteins. Furthermore, the results suggest that
normally ERCC1 enters the nucleus as a heterodimer with XPF,
and is retained in the cytoplasm with XPF when XPF is misfolded.
To rule-out the possibility that the abnormal subcellular
localization of XPF-ERCC1 was an artifact of immunofluores-
cence, wt and XPF
R153P fibroblasts were fractionated and XPF-
ERCC1 was detected by immunoblot in the nuclear and
cytoplasmic fractions (Figure 2C). In normal cells (C5RO), XPF-
ERCC1 is predominantly nuclear. XPF-ERCC1 was also detected
in the cytoplasmic fraction, but to an extent that could be
attributed to nuclear contamination, as determined by immuno-
detection of the nuclear protein nucleophosmin. In contrast,
substantially more XPF and ERCC1 were detected in the
cytoplasm than in the nucleus of XP51RO cells. Similar results
were obtained for other XPF mutant cell lines (XP24BR, XP26BR
and XP32BR) and using other antibodies against XPF and
ERCC1 (data not shown). Degradation products of both ERCC1
and XPF are commonly detected on immunoblot, but were not
overrepresented in the mutant cells. These data confirm the
immunofluorescence data and support the conclusion that
mislocalization of XPF-ERCC1 in the cytoplasm occurs in XPF
mutant cells.
Figure 1. Biochemical characterization of XPF
R153P-ERCC1 and
XPF
R799W-ERCC1 mutants. (A) Gel filtration profiles from the
purification of recombinant XPF-ERCC1, XPF
R153P-ERCC1 and XPF
R799W
-ERCC1 from baculovirus-infected Sf9 insect cells using a His6 tag on
ERCC1. Aggregated proteins elute at ,45 ml in the void volume of the
column; heterodimeric XPF-ERCC1 elutes at ,65 ml, corresponding to
,200 kD, and monomeric ERCC1 elutes at ,78 ml (,50kD). (B) SDS
PAGE analysis of purified protein complexes. Lane 1, 3 and 5 (D): XPF-
ERCC1, XPF
R153P-ERCC1 and XPF
R799W-ERCC1, respectively, after
purification over NTA-agarose, gel filtration and heparin columns.
Lanes 2 and 4 (A) show the proteins present in the fractions eluting at
45 ml in the gel filtration column step of XPF
R153P-ERCC1 and XPF
R799W
-ERCC1, respectively. (C) Immunodetection of XPF in normal (C5RO) and
XPF mutant cells. The star indicates the migration of a cross-reactive
band demonstrating equal loading [32]. (D) Incision activities of XPF-
ERCC1, XPF
R153P-ERCC1 and XPF
R799W-ERCC1 (200 fmol) on a 59-
32P-
labeled stem-loop DNA substrate (100 fmol) in the presence of either
0.4 mM MnCl2 (lanes 2, 4 and 6) or 2 mM MgCl2 (lanes 3, 5 and 7).
Reactions were analyzed on a 15% denaturing polyacrylamide gel. The
46-mer substrate and 9–10-mer products are indicated.
doi:10.1371/journal.pgen.1000871.g001
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PLoS Genetics | www.plosgenetics.org 3 March 2010 | Volume 6 | Issue 3 | e1000871Figure 2. Differential immunofluorescence of cells from patients with XPF mutations. Fibroblasts from patients with mutations in XPF and
a normal control were grown in the presence of different size beads. After 24 hr the cultures were washed to remove extracellular beads, mixed and
co-plated on glass coverslips. The next day, the cells were fixed and immunostained as indicated. Cells were stained with Dapi to identify nuclei and
examined by phase contrast microscopy to identify the cell type by their bead content and by fluorescence microscopy for immunodetection of XPF
or ERCC1. (A) Analysis of XPF protein sub-cellular localization. Cells from an unaffected individual were labeled with 2 mM beads; XPF mutant cells
were labeled with 0.8 mM beads. (B) Analysis of ERCC1 subcellular localization in patients with mutations in XPF. (C) Immunodetection of XPF and
ERCC1 in nuclear and cytoplasmic fractions of normal fibroblasts (C5RO) and XPF mutant cells (XP51RO). Tubulin is used as a loading control of the
cytoplasmic fraction. Nucleophosmin is used as a loading control for the nuclear fraction. (D) Quantitation of the fraction of cells containing
exclusively nuclear XPF-ERCC1, XPF-ERCC1 in the nucleus and cytoplasm (pancellular) or exclusively cytoplasmic complex, as determined from
immunofluorescence images (n$100 cells per cell line).
doi:10.1371/journal.pgen.1000871.g002
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immunofluorescence in all XPF mutant cells within a population.
To quantify the phenomena, the fractions of cells with exclusively
nuclear, exclusively cytoplasmic, or pancellular XPF-ERCC1 were
determined from immunofluorescence images (Figure 2D). In wt
fibroblasts, 93% of cells have XPF-ERCC1 only in the nucleus.
Seven percent of cells show pancellular XPF-ERCC1. But never is
the complex seen exclusively in the cytoplasm. In all of the XPF
mutant cell lines, XPF-ERCC1 was detected exclusively in the
cytoplasm of a fraction of cells ranging from 3–46% of the total
population. Thus all known XPF mutations lead to a reduction in
nuclear XPF-ERCC1 and an increase in the amount of the
complex detected in the cytoplasm.
Direct detection of XPF
R153P
To further rule out the possibility that the cytoplasmic XPF-
ERCC1 detected was an artifact generated by non-specific
antibodies, human XPF
R153P and XPF
WT were tagged with YFP
and expressed in Xpf mutant hamster cells (UV41) for direct
detection of XPF protein. The expression of fusion proteins was
confirmed by immunoblot using antibodies against human XPF
and GFP (Figure 3A). Immunodetection of XPF revealed
overexpression of both fusion proteins relative to endogenous
XPF protein levels in normal fibroblasts (C5RO). Numerous
breakdown products of XPF were also observed, likely due to its
overexpression. But only a single fusion protein migrating at the
expected molecular mass of full length XPF-YFP was detected
using an antibody that detects GFP. To determine if the fusion
proteins were functional, transiently transfected cells were tested
for their sensitivity to UV to measure NER and mitomycin C
(MMC) to measure interstrand crosslink repair (Figure 3B). Wild-
type XPF-YFP yielded near complete correction of the hypersen-
sitivity of UV41 mutant cells to UV and MMC. By contrast,
despite the fact that XPF
R153P_YFP was overexpressed to the same
extent as XPF
WT-GFP, this protein was unable to correct either
DNA repair defect (Figure 3B), as expected based on the
hypersensitivity of the XP51RO patient cell lines [32]. To
determine the sub-cellular localization of XPF
R153P, cells express-
ing the YFP-tagged protein were plated on glass coverslips and the
protein detected by fluorescence microscopy (Figure 3C). XPF
WT-
YFP was exclusively in the nucleus. However, XPF
R153P_YFP was
detected in the cytoplasm of 95% of the transfected cells. This
confirms the immunodetection data indicating that mutant XPF is
cytoplasmic.
Characterization of XPF
R153P-ERCC1 activity in living cells
Unscheduled DNA synthesis (UDS) measures the incorporation
of radiolabeled nucleotides into the genome of non-S phase cells
after exposure to UV radiation and is a direct measure of NER
[35]. Previously, UDS in cells from patient XP42RO (XPF
R799W)
and XP51RO (XPF
R153P) was reported to be 20% and ,5% of
that in normal fibroblasts, respectively (Table 1). UV-induced
UDS was measurable in all of the mutant XPF cell lines except
XP51RO. This demonstrates that all of the mutant XPF proteins,
with the exception of XPF
R153P, retain catalytic activity in vivo.
To ask if XPF
R153P is also catalytically active in vivo,
recombinant, purified XPF
R153P-ERCC1 was microinjected into
the nuclei of NER-deficient XP51RO primary fibroblasts to
determine if UV-induced UDS could be restored. XP51RO cells
were first fused on slides by treatment with inactivated Sendai
virus to produce homopolykaryons (multinucleate cells). Only
homopolykaryons were injected with protein, to permit identifi-
cation of those cells that were injected with protein. The slides
were irradiated with 10 J/m
2 UV-C, cultured in the presence of
Figure 3. Characterization of XPF-YFP and XPF
153-YFP in CHO
cells. (A) Western blot analysis of XPF-YFP expressed in Xpf mutant
cells. XPF-deficient hamster cell line, UV41, was transiently transfected
with wild type XPF-YFP or XPF
153-YFP and the fusion proteins were
detected using an antibody against XPF or GFP. C5RO was used as
positive control for the XPF blot and as a negative control for the GFP
blot. UV41 cells transfected with YFP alone was used as a negative
control for XPF blot and as a positive control for GFP blot.
(B) Clonogenic survival of wild-type (wt), XPF-deficient CHO cell line
UV41, and UV41 transfected with wild type XPF-YFP and XPF
153-YFP
after UV and MMC treatment. Colonies were counted 7–10 days after
treatment and results are plotted as mean 3 independent experiments.
(C) Subcellular localization of wild type XPF-YFP and XPF
153-YFP after
transient transfection in XPF-deficient the CHO cell line UV41 detected
by fluorescence microscopy.
doi:10.1371/journal.pgen.1000871.g003
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incorporation in non-S phase cells measured (Figure 4). As
expected, delivery of XPF
WT-ERCC1 to the nuclei of cells led to a
significant increase in the number of grains detected in homo-
polykaryons relative to individual cells in the same culture
(Figure 4A). A significant increase in UV-induced UDS was also
detected in homopolykaryons injected with XPF
R153P-ERCC1
(Figure 4C). This confirms the in vitro activity data and establishes
that XPF
R153P is catalytically active in vivo if it is delivered to the
nucleus. UDS levels were not recovered to the same extent as
when WT protein was injected (Figure 4D). But injection of
XPF
R153P-ERCC1 or XPF
R799W-ERCC1 led to a similar increase
in UDS. This suggests that the incomplete recovery of DNA repair
is due to decreased concentration of the recombinant mutant
proteins relative to XPF
WT-ERCC1 (Figure 1). These data support
the conclusion that mislocalization of XPF-ERCC1 contributes to
the DNA repair defect and symptoms caused by XPF mutations.
Clinical correlation
To determine if the severity of disease associated with a
particular mutation in XPF could be predicted by the amount of
XPF-ERCC1 detected in cell nuclei, the results in Figure 2D
were compared to the clinical information available about the
patients from which the cells were derived. In Table 1, the cell
lines are listed in order of decreasing UDS. Patients with mild
d i s e a s et e n dt oh a v eg r e a t e rU D So rD N Ar e p a i r .P a t i e n t s
XP32BR and XP26BR could be exceptions, but they are too
young to know the full extent of their disease. In Figure 2D, the
cell lines are clustered into those from patients in which severe
disease/neurodegeneration was documented (right) or not yet
observed (left). There is a trend towards those with severe disease
to have more cells with non-nuclear XPF-ERCC1, but this trend
did not reach significance (p=0.06, unpaired Student’s t-test),
likely due to the small sample size. Therefore, the detection of
cells with cytoplasmic XPF-ERCC1, while maybe useful to
screen for patients with XPF mutations is not sufficient to predict
patient prognosis.
Discussion
Classically, inherited mutations in a gene are associated with a
single disease. However, mutations in several genes involved in the
NER pathway can result in more than one disease. The most
prominent example is XPD, which if mutated can cause the
cancer-prone disease XP but also Cockayne Syndrome (CS)
characterized by photosensitivity, growth retardation, develop-
mental abnormalities and profound neurodegeneration, as well as
trichothiodystrophy (TTD), which is similar to CS, but also
involves the skin and nails [36]. Similarly, mutations in XPB can
also cause XP, TTD and a combined XP-CS [37] and mutations
in XPG can lead to XP or XP-CS [38]. Of all the genes whose
products are required for NER, only XPB, XPD and XPG are
required for the proper function and stability of the basal
transcription factor TFIIH [39]. Thus the more severe symptoms
of CS and TTD are attributed to a combined defect in NER as
well as transcription [36,40–42]. Mutations in XPF were recently
linked to a second disease in addition to XP, a disease of systemic
accelerated aging termed XFE progeroid syndrome [32]. In this
study, we sought to determine how mutations in XPF can lead to
such a wide variety of symptoms.
Table 1. Characteristics of XPF mutant cell lines.
Patient
Mutation
Allele 1
Mutation
Allele 2 Age (yr)
Skin
Cancer Clinical features UDS UV sensitivity
% of cells with
non-nuclear XPF-
ERCC1 Ref
C5RO none none – normal 100% 1X 7% [33]
Father of
XP42RO
R799W none – photosensitivity without skin
lesions
100% 1X rare [33]
XP23OS 455fs ?
* 45 – mild XP 45% 4X rare [60]
XP7NE P379S silent 28 – mild XP 30% 2X 27% [61]
XP62ROu R799W R799W mild XP with late onset
neurodegeneration
20% not reported 65%
XP42ROu R799W R799W 62 + mild XP with late onset
neurodegeneration
20% 2X 33% [33]
XP2YO T567A ?
¤ 657fs 65 + mild XP 17% 3X n.d. [46]
AS871 R589W del exon3 severe XP with
neurodegeneration
15% 2X 59%
XP26BR R799W R799W mild XP 15% not reported 33%
XP32BR R589W P379S 12 – mild XP 10% 2X 39%
XP24BR R799W R589W 29 – severe XP with
neurodegeneration
5% 3X 74% [61]
XP24KY R799W 537fs + 7bp 50 – XP with late onset
neurodegeneration
7% 3X 45% [46]
XP51RO R153P R153P 16 – neurodegeneration severe
progeria
,5% 10X .33% [30]
UDS unscheduled DNA synthesis
*The patient had normal levels of XPF transcript, suggesting one allele encodes a full-length mRNA.
¤Mutation could not be confirmed on genomic DNA.
u Siblings.
n.d. = not determined
doi:10.1371/journal.pgen.1000871.t001
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Since CS and TTD are attributed to defects in transcription
[34,43], the prediction is that mutations in XPB, XPD or XPG that
cause CS or TTD should affect basal transcription in addition to
NER, whereas mutations that affect only NER cause XP. Indeed,
mutations in the catalytic domain of XPG, for example A
792V,
disrupt the endonuclease activity of XPG, but not its interaction
with TFIIH and therefore causes classical XP [44]. Similarly, a
mutation in the helicase domain of XPD, D
234N, affects NER, but
not basal transcription and therefore leads to XP [45]. By analogy,
we examined the enzymatic activity of XPF
R153P and XPF
R799W,
which cause XFE progeroid syndrome and XP respectively, and
discovered that neither mutation ablates the catalytic activity of
the protein. Recombinant protein complexes harboring either
mutation are able to incise a stem-loop substrate in vitro (Figure 1)
and to restore NER in vivo (Figure 4). This is in keeping with the
fact that patients with XP-F have residual UDS or NER (Table 1).
Intriguingly, XP-F patients tend to have much milder photosen-
sitivity and later onset skin cancer than XP patients from other
complementation groups with the same level of UDS [46]. One
explanation for this is that NER occurs in XP-F cells but at a much
slower rate [47], making UDS a relatively poor reflection of the
true DNA repair capacity of a cell. In total, these data provide
clear evidence that viable mutations in XPF do not ablate catalytic
activity of the XPF-ERCC1 nuclease. Of note, all XP patients for
which the mutation in XPF was confirmed by sequencing genomic
DNA harbor one of three recurrent point mutations (R799W,
R589W or P379S). The rarity and limited repertoire of only
hypomorphic point mutations in patients strongly suggests that
XPF-ERCC1 nuclease activity is essential for normal embryonic
development.
Stability of XPF
R799W-ERCC1 and XPF
R153P-ERCC1 is
reduced
Mutations in a single gene could lead to diverse clinical outcomes
if mutations differentially affect the stability of the gene product. For
example, mutations affecting the stability of the TFIIH complex are
linked with TTD but not XP [34]. Total cellular XPF and ERCC1
are dramatically reduced in cells from a patientwithXFE progeroid
syndrome (Figure 2C). However, XPF levels are reduced to the
same extent in whole cell extracts from a patient with mild disease
and 20% of the normal level of NER (Figure 1C). Therefore,
mutations in XPF clearly affect protein level, which undoubtedly
contributes to reduced DNA repair and disease. However, the level
of XPF-ERCC1 in patient cells, as detected by immunoblotting, is
inadequate to explain the differences in the severity in the DNA
repair defect and disease between patients with different mutations
in XPF. Interestingly, in at least a subset of XP-F patients, XPF
mRNA levels are normal, but XPF protein level is low [46],
indicating that mutant XPF is unstable.
Mutations in XPF affect protein subcellular localization
The novel and unexpected finding is that mutation in XPF leads
to increased cytoplasmic localization of the XPF-ERCC1 nuclease
complex (Figure 2 and Figure 3) and that this aberrant subcellular
localization is what prevents XPF-ERCC1 from participating in
DNA repair (Figure 4). This was demonstrated by immunofluo-
rescence detection of the complex using multiple antibodies. The
results were confirmed by examining the subcellular localization of
fluorescently tagged recombinant XPF (Figure 2). In further
support of this, ERCC1 is also mislocalized to the cytoplasm of
cells from the one patient reported with a mutation in ERCC1
[48].
Figure 4. Correction of XPF mutant cell NER defect by
microinjection of XPF-ERCC1. Primary fibroblasts from XFE proger-
oid patient XP51RO were fused to create homopolykaryons by
treatment with inactivated Sendai virus then plated on glass coverslips.
Only homopolykaryons were injected with recombinant XPF-ERCC1
protein complex (A) wild-type (B) XPF
R799W-ERCC1 (C) XPF
R153P-ERCC1.
The cultures were irradiated with 10 J/m
2 UV-C and
3H-thymidine was
added to the culture. UV-induced unscheduled DNA synthesis was
detected by autoradiography. Homopolykaryons are indicated with
arrows. (D) Histogram indicating the average number of radiographic
grains in nuclei injected with each of the recombinant protein
complexes and uninjected cells in the same sample. Error bars indicate
the standard deviation. N indicates the number of nuclei analyzed in
each population. P values for the comparison between injected and
uninjected cells were calculated using an unpaired two-tailed Student’s
t-test.
doi:10.1371/journal.pgen.1000871.g004
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cells harboring XPF or ERCC1 mutations, suggesting the possibility
that mutations affect proper folding of XPF-ERCC1 and that
misfolded proteins are preferentially sequestered in the cytoplasm
through interactions with other proteins or preferentially degrad-
ed. Alternatively, there may be tremendous selection for cells with
nuclear XPF-ERCC1. This is consistent with the notion that the
repair complex is essential for viability. Indeed, continuous
passaging of XP51RO cells over years leads to a striking increase
in the fraction of cells with nuclear XPF-ERCC1 and reduced
sensitivity to the crosslinking agent mitomycin C (Ahmad,
Bhagwat and Niedernhofer, unpublished data). Thus the fraction
of cells with cytoplasmic XPF-ERCC1 may be underrepresented
in Figure 2D, although only early passage cells were used in this
study.
Disease caused by protein mislocalization
Many human diseases are caused by misrouting or mislocaliza-
tion of proteins, ranging from metabolic disorders to cancer.
Mislocalization of the tumor suppressors p53 [49], FOXO [50],
p27
Kip1 [51] and b-catenin [52] into the cytoplasm rather than the
nucleus, leads to a loss of protein function and is associated with
cancer. In contrast, mislocalization of NF-kB [53], BRCA1 and
BARD1 [53,54] from the cytoplasm into the nucleus is also
associated with a variety of tumors. A classic example of a disease
caused by protein mislocalization is cystic fibrosis which is caused
by retention of the cystic fibrosis transmembrane conductance
regulator (CFTR) protein in the endoplasmic reticulum, instead of
its localizing to the cell surface [55,56]. In addition, nephrogenic
diabetes inspidus, retinitis pigmentosa, emphysema and a1-
antitrypsin deficiency liver disease are also caused by mislocalized
proteins [55].
Mislocalization of proteins may result from a mutated nuclear
localization sequence (NLS) or nuclear export sequence (NES).
Remarkably, the majority of the missense mutations in XPF is at
arginine residues and leads to conversion of the arginine to a
noncharged residue. So these mutations could affect a complex
NLS. All of the point mutations (RRP, RRW and PRS) are also
predicted to alter protein structure, supporting the notion that XPF
mutations affect protein folding and/or protein:protein interac-
tions that are critical for nuclear localization.
Our data add XPF to the list of proteins that if mislocalized
contribute to disease. While this leads to novel insight into the
regulation of XPF-ERCC1 and DNA repair in cells, the extent of
XPF-ERCC1 mislocalization, as measured by immunodetection,
does not predict the level of NER (UDS) or disease severity
(Table 1). This could be because each mutation differentially
affects folding of the protein and thereby differentially affects
protein expression, protein degradation and/or cellular localiza-
tion. Another possibility is that there are modifier proteins that
influence disease severity, in particular in patients with homozy-
gous mutations. However, we believe the former is of primary
importance based on the observation that titration the level of
expression of ERCC1-XPF in mice directly impacts lifespan and
the severity of symptoms [57,58].
In the case of XPF, it is the absence of XPF and its binding
partner ERCC1 in the nucleus leading to reduced repair of
genomic DNA that is disease-causing, rather than toxicity of
mislocalized protein. Our data illustrate a novel mechanism by
which the DNA repair capacity of a cell is determined: by nuclear
localization of XPF-ERCC1. The identification of proteins that
regulate this could lead to novel targets for improving DNA repair
to treat patients with mutations in XPF or reduce cancer risk after
exposure to genotoxic agents. Alternatively, these proteins would
be excellent targets for small molecule inhibitors that would reduce
repair and thereby prevent tumor resistance to genotoxic cancer
therapies.
Materials and Methods
Biochemical characterization of XPF
R153P-ERCC1 and
XPF
R799W-ERCC1
Purification of recombinant XPF–ERCC1 was performed
essentially as previously reported [27] from baculovirus-infected
Sf9 insect cells using a His6 tag on ERCC1. In brief, plasmids
pFastBac1-XPF and pFastBac1-ERCC1-His were used to transfect
Sf9 insect cells, and to amplify the virus according to the
manufacturer’s instructions (BAC TO BAC system; Life Technol-
ogies). Cell extracts were prepared 65 hr after infection with an
MOI of 5 and highly purified protein was obtained using
chromatography on Ni2agarose, gel-filtration and heparin
columns. Only XPF-ERCC1 eluting as proper heterodimer on
the gel filtration column at ,65 ml of eluant was collected. The
aggregated protein, eluting in the void volume (,40–50 ml), was
not used in experiments.
The endonuclease activity of wild-type and mutant XPF-
ERCC1 was performed using a stem2loop substrate also as
previously described [27]. A stem122loop22 oligonucleotide
(GCCAGCGCTCGGT22CCGAGCGCTGGC) was 59-
32P end-
labeled. Nuclease reactions were performed on 100 fmol of DNA
substrate and 20–200 fmol of XPF-ERCC1 protein in a total
volume of 15 ml in optimized nuclease buffer (25 mM HEPES
pH 8.0, 40 mM NaCl, 10% glycerol, 0.5 mM b-mercaptoethanol,
0.1 mg/ml bovine serum albumin and 0.4 mM MnCl2 or 2 mM
MgCl2). The reactions were incubated at 30uC for 2 h and
stopped by adding 15 ml of 90% formamide/10 mM EDTA and
heating at 95uC for 5 min. Samples were loaded onto 15%
denaturing polyacrylamide gels and reaction products were
visualized by autoradiography and quantified on a PhosphorIma-
ger (STORM860; Molecular Dynamics).
Cell lines and culturing
Human fibroblasts immortalized with hTert were cultured in
Ham’s F10 with 10% fetal calf serum and antibiotics and
incubated at 3% oxygen as described previously [32]. Cell lines
included those derived from a normal individual (C5RO) [59], the
parent of a patient, heterozygous for a mutation in XPF [33], XP-F
patients (XP42RO) [33], XP23OS [60], XP24KY [46], XP7NE
[61], XP32BR, XP26BR, XP24BR [61], and XP62RO, and a
patient with XFE progeroid syndrome caused by a mutation in
XPF (XP51RO) [32]. Unscheduled DNA synthesis (UDS) in these
cells lines was previously reported as referenced above and
confirmed in mixed cultures (XP-F cells co-cultured with normal
cells using a more accurate click-staining method, as recently
described [62].
Immunodetection of XPF in patient cells
Cells were trypsinized, washed twice with PBS and lysed with
1 ml NETT buffer (100 mM NaCl, 50 mM Tris base pH 7.5,
5 mMEDTA pH 8.0,0.5%TritonX-100)containingComplete
TM
mini protease inhibitor cocktail and phosphatase inhibitor cocktail
(Roche Molecular Biochemicals). Then the lysates were freeze-
thawed twice in liquid nitrogen to disrupt nuclear membranes.
From each sample, 50 mg of protein was resolved on 10% SDS-
PAGEgels afterboiling for10 mininthe presence ofloadingbuffer.
XPF was detected using a human XPF monoclonal antibody (clone
219; Neomarkers, Fremont, CA) at a dilution of 1:1000.
Mislocalization of XPF-ERCC1 Causes Disease
PLoS Genetics | www.plosgenetics.org 8 March 2010 | Volume 6 | Issue 3 | e1000871Differential immunofluorescence of fibroblasts isolated
from patients with mutations in XPF
Cultures of primary human fibroblasts from patients with
mutations in XPF or a normal individual were grown in the
presence of different size beads (2 mm or 0.8 mm; Sigma). After
24 hr the cultures were trypsinized and washed extensively with
phosphate-buffered saline to remove any extracellular beads. The
cells were then mixed in various combinations and co-plated on
glass coverslips to provide internal controls of normal XPF-
ERCC1 protein levels [34]. After 16 hr, the cells were fixed with
2% paraformaldehyde in sodium phosphate buffer, pH 7.4, for
15 min then permeabilized with 0.1% Triton X-100 in PBS. The
samples were immunostained with polyclonal anti-ERCC1
(1:2000; [63]) or polyclonal anti-XPF (1:1000; [16]) followed by
goat anti-rabbit ALEXA 488 (1:500; Molecular Probes). Samples
were stained with Dapi to identify nuclei and examined by phase
contrast microscopy to identify the genotype of the cells according
to their bead content and by fluorescence microscopy for
immunodetection of repair proteins.
Cell fractionation. Cells were fractionated into nuclear and
cytosolic fractions as described [64], with minor modification. In
brief, cells were trypsinized, pelleted and washed twice with PBS.
The pellet was vortexed at maximum speed for 15 sec with 200 ml
of CERI reagent from the Pierce NE-PER fractionation kit (Pierce
Biotech) with Complete
TM mini protease inhibitor cocktail, then
incubated on ice for 10 min. This was followed by addition of
11 ml of CERII, vortexing for 5 sec and incubation on ice for
1 min. The mixture was spun at 13,000 rpm for 5 min and the
supernatant collected as the cytosolic fraction. The nuclei in the
pellet were suspended in extraction buffer (15 mM Tris-HCl
pH 7.3, 1 mM EDTA, 0.4 M NaCl, 1 mM MgCl2, 10% glycerol,
10 mM b-mercaptoethanol and Complete
TM mini protease
inhibitor cocktail), mixed for 1 hr at 4uC and spun down at
13,000 rpm for 10 min. The supernatant was collected as the
soluble nuclear fraction.
Subcellular localization of XPF–YFP in Chinese hamster
Ovary (CHO) cells
XPF cDNA was cloned into pYFP-N1 (BD Biosciences
Clontech, Palo Alto, CA) such that YFP was expressed as fusion
protein at the C-terminus of XPF. This construct, pXPF-YFP-N1,
was then used to create XPF
R153P-YFP by QuickChange
R Site-
Directed Mutagenesis Kit (Stratagene, Cedar Creek, TX)
according to the manufacturer’s instructions. The wild type and
mutant constructs were transfected in XPF-deficient CHO cell
lines UV41 or UV47 using lipofectamine 2000 (Invitrogen,
Carlsbad, CA) following the manufacturer’s instructions. Cells
expressing YFP were flow sorted using Dako Cytomation MoFLo
high-speed cell sorter (Dako North America, Carpinteria, CA) 24–
48 hrs after transfection.
To study the subcellular localization of XPF, YFP-positive
CHO cells were plated on glass coverslips and grown to 95%
confluency. The next day, the samples were fixed with 2%
paraformaldehyde in sodium phosphate buffer, pH 7.4, for
15 min. The cells were permeabilized with 0.1% Triton X-100
in phosphate-buffered and nuclei were stained with Dapi-vector
shield (Vector Laboratories, Inc. Burlingame, CA). XPF-YFP was
visualized using an Olympus BX51 fluorescent 4 microscope at
60–100X magnification.
Clonogenic survival assays of wild-type and mutant CHO
cells
Wild type (AA8), XPF-deficient (UV41), XPF-YFP and
XPF
R153P-YFP cells were seeded in 6 cm dishes in triplicate at
10
3–10
4 cells per plate, depending on the dose of genotoxin. After
16 hr, the cells were irradiated with UV-C or exposed to
mitomycin C (MMC). After approximately one week, the cultures
were fixed and stained with 50% methanol, 7% acetic acid and
0.1% Coomassie blue. Colonies, consisting of at least 10 cells, were
counted using a Nikon SMZ 2B 15 stereomicroscope microscope
with 10X eyepiece. The data were plotted as the number of
colonies that grew on the treated plates relative to untreated plates
6 the standard error of the mean for 2–3 independent
experiments.
Immunoblotting of XPF in Wt and mutant CHO cells
Whole cell extracts were prepared from C5RO and UV41 cells
transfected with vectors expressing YFP, XPF-YFP or XPF
R153P-
YFP. Proteins were separated by SDS PAGE using a 10% gel.
XPF was detected using a human XPF monoclonal antibody
(clone 219; Neomarkers, Fremont, CA) at a dilution of 1:1000.
YFP was detected using a GFP monoclonal antibody (Clones 7.1
and 13.1; Roche, Indianapolis, IN) at a dilution of 1:1000.
Correction of XPF mutant cell UV sensitivity by micro-
injection of recombinant XPF-ERCC1
Microinjection of purified proteins was performed as previously
described [65,66]. Briefly, primary human fibroblasts from
XP51RO were fused by treating cultures with inactivated Sendai
virus and then plated on glass coverslips. Subsequently, purified,
recombinant XPF-ERCC1 protein complex (wild type or
containing the R799W or R153P substitution in XPF) was
injected into the nuclei of homopolykaryons. The cultures were
irradiated with 10 J/m
2 UV-C and pulse labeled for 3 hrs with
3H-thymidine. Unscheduled DNA synthesis (UDS) was detected
by autoradiography.
One to ten femtoliters of a 10–100 nM solution was injected
into the nuclei of 10–20 homopolykaryons for each of the three
recombinant proteins and the number of radiographic grains
counted in at least 20 nuclei of the homopolykaryons and a similar
number of nuclei of single cells in the same sample. The mean and
standard deviation of the number of grains was calculated for each
of the three proteins. An unpaired, two-tailed Student’s t-test was
used to determine if there was a significant difference in
unscheduled DNA synthesis between cells that were injected with
recombinant XPF-ERCC1 and cells that were not injected.
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